News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,898 Results
Type
Article (13891)
Company Profile (101)
Press Release (252906)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88394)
Career Advice (469)
Deals (15416)
Drug Delivery (67)
Drug Development (36667)
Employer Resources (49)
FDA (6321)
Job Trends (6232)
News (150770)
Policy (14115)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (455)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23314)
ALS (36)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (38)
Approvals (6358)
Artificial intelligence (106)
Autoimmune disease (9)
Automation (3)
Bankruptcy (149)
Best Places to Work (4397)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (16)
Breast cancer (78)
Cancer (602)
Cardiovascular disease (71)
Career advice (411)
Career pathing (11)
CAR-T (22)
Cell therapy (88)
Cervical cancer (4)
Clinical research (30955)
Collaboration (336)
Compensation (152)
Complete response letters (17)
COVID-19 (758)
CRISPR (20)
C-suite (121)
Cystic fibrosis (37)
Data (628)
Denatured (15)
Depression (9)
Diabetes (78)
Diagnostics (1327)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (64)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32246)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37630)
Executive appointments (384)
FDA (6740)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (212)
Gene editing (38)
Generative AI (9)
Gene therapy (102)
GLP-1 (347)
Government (1323)
Grass and pollen (2)
Guidances (16)
Healthcare (3608)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (794)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (15)
Intellectual property (47)
Interviews (60)
IPO (5905)
IRA (29)
Job creations (2056)
Job search strategy (377)
Kidney cancer (6)
Labor market (11)
Layoffs (180)
Leadership (3)
Legal (3443)
Liver cancer (19)
Lung cancer (80)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (151)
MASH (32)
Medical device (1307)
Medtech (1309)
Mergers & acquisitions (9717)
Metabolic disorders (257)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (578)
NextGen: Class of 2025 (1603)
Non-profit (604)
Northern California (710)
Now hiring (7)
Obesity (147)
Opinion (119)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (46)
Partnered (7)
Patents (115)
Patient recruitment (29)
Peanut (10)
People (29017)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8050)
Phase II (13095)
Phase III (11764)
Pipeline (439)
Policy (70)
Postmarket research (1401)
Preclinical (3228)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (167)
Real estate (2659)
Recruiting (17)
Regulatory (10153)
Reports (14)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (36)
Series A (36)
Series B (12)
Service/supplier (3)
Sickle cell disease (32)
Southern California (720)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1633)
State (2)
Stomach cancer (3)
Supply chain (31)
Tariffs (21)
The Weekly (30)
United States (7162)
Vaccines (152)
Venture capitalists (14)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Today (1)
Last 7 days (176)
Last 30 days (803)
Last 365 days (11848)
2025 (3447)
2024 (12556)
2023 (14309)
2022 (19634)
2021 (20179)
2020 (19148)
2019 (15036)
2018 (11829)
2017 (13945)
2016 (13185)
2015 (15535)
2014 (12461)
2013 (10652)
2012 (11440)
2011 (11984)
2010 (10935)
Location
Africa (315)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20189)
Australia (2619)
California (1718)
Canada (905)
China (235)
Colorado (66)
Connecticut (67)
Delaware (54)
Europe (39566)
Florida (322)
Georgia (38)
Idaho (9)
Illinois (195)
India (16)
Indiana (135)
Iowa (1)
Japan (91)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (253)
Massachusetts (1474)
Michigan (31)
Minnesota (93)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (764)
New Mexico (7)
New York (500)
North Carolina (386)
North Dakota (2)
Northern California (710)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (438)
Puerto Rico (8)
Rhode Island (9)
South America (509)
South Carolina (2)
Southern California (720)
Tennessee (34)
Texas (227)
Utah (33)
Virginia (72)
Washington D.C. (31)
Washington State (116)
Wisconsin (15)
266,898 Results for "aqua pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
December 5, 2024
·
3 min read
Deals
Elanco Announces Sale of Aqua Business for $1.3 Billion
Elanco Animal Health Incorporated announced it has entered into an agreement to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash, which represents approximately 7.4x the estimated 2023 revenue of the Elanco aqua business.
February 5, 2024
·
8 min read
Press Releases
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with ‘Neurophet AQUA’
November 25, 2024
·
3 min read
Deals
Merck Animal Health to Acquire Elanco’s Aqua Business
Merck Animal Health announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species.
February 5, 2024
·
7 min read
Press Releases
Neurophet to launch total solution for AD treatments ‘Neurophet AQUA AD’ at AAIC 2024
July 25, 2024
·
3 min read
Neurophet receives FDA 510(k) Clearance for Neurophet AQUA
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that the US Food and Drug Administration (FDA) 510(k) has cleared “Neurophet AQUA”.
May 18, 2023
·
3 min read
Aqua-Yield Announces $23 Million Series A Funding Round
Aqua-Yield, the leading nanoliquid company for agricultural production worldwide, today announced the close of its Series A investment round of $23M.
September 13, 2022
·
5 min read
Press Releases
AquaBounty Technologies Announces Full Year 2024 Financial Results
March 27, 2025
·
10 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 26,690
Next
